INAB
IN8bio, Inc. Common StockstockNASDAQ
At CloseNov 18, 2026 10:27:52 AM EST
0.79USD-3.646%(-0.03)30,768
Pre-marketNov 18, 2026 8:43:30 AM EST
0.801USD-2.317%(-0.019)
After-hoursNov 18, 2026 4:00:30 PM EST
0.78USD-1.278%(-0.01)
Loading…
Loading…
8.43M
Healthcare
Biotechnology
HQ
New York, NY, USA
Previous Close
$0.82
Beta
1.40
52-Week High
$2.73 2026-01-16
52-Week Low
$0.72 2026-11-16
SMA 50
$1.08
SMA 200
$1.37
Avg. Vol 10D
542,485
Avg. Vol 30D
206,193
Avg. Vol 90D
107,733
Relative Vol
0.15
10.81M
8.13M
75.21%
15,733
0.22%
1.00
33%/67%
5.47%
4.4700%
200,000
607
607
Jun 6, 2025 · 1-for-30 (reverse)
-19.4M
-1.19
-141.83
Nov 16, 2026
IN8bio reports survival data from glioblastoma trial ·
Investing.com
Nov 6, 2026
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ·
GlobeNewswire Inc.
INAB Profile
in8bio, inc. ("in8bio") is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
INAB Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.82 | 2026-11-12 | -4.86% | -1.476 |
| 1M | 1.09 | 2026-10-19 | -28.40% | 1.645 |
| 3M | 1.20 | 2026-08-19 | -34.97% | 1.412 |
| 6M | 1.45 | 2026-05-19 | -46.18% | 1.185 |
| 1Y | 1.62 | 2025-11-19 | -51.83% | 1.402 |
| 2Y | 9.51 | 2024-11-19 | -91.79% | — |
| 5Y | 204.00 | 2021-11-19 | -99.62% | 0.496 |
INAB Stock Summary
IN8bio, Inc. Common Stock (NASDAQ:INAB) stock price today is $0.78, and today's volume is 30,768. INAB is down 4.829% today. The 30 day average volume is 206,193. INAB market cap is $8.43M with 10.81M shares outstanding.